This cooperativity is in accord with human prostate cancer genomic data, where TP53 alteration rate (mutation or copy number loss) is significantly higher in ETS fusion–positive samples than that in ETS fusion–negative samples (Fig. 4A) (3). This evidence concerns the gene TP53 and prostate carcinoma.